SE OF ORAL TILACTASE ENZYMES IN SUBJECTS WITH LACTOSE MALABSORPTION AND INTOLERANCE. CLINICAL RELEVANCE IN A POPULATION WITH HIGH PREVALENCE OF LACTASE DEFICIENCY IN SOUTHERN ITALY. - TILATT/0708

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE0 个研究点开始时间: 2012年1月9日最近更新: 2012年4月18日

适应症

试验速览

暂无简介。

•Subjects with persisting symptoms (i.e. longer than 6 months) located either in the upper and/or lower abdomen suggestive of lactose intolerance, fructose intolerance, small intestinal bacterial overgrowth (SIBO), functional gastrointestinal disorders (i.e. irritable bowel, functional dyspepsia, functional diarrhea)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Subjects with alarm symptoms (e.g. anaemia, unexplained weight loss, chronic pain, ineffective therapies) or older than 50 years will be further investigated with upper a/o lower endoscopy and blood tests in order to rule out inflammatory bowel diseases, celiac disease, intestinal neoplasms, colonic diverticula, and thyroid diseases. If needed, patients will undergo Rx barium enema for characterization of colonic diverticula and severe dolicocolon, as a potential cause of lower intestinal symptoms. Excluded from the study will be also non-compliant subjects or those with an history of liver, renal, lung, heart, metabolic, or neurological disease and those taking laxatives, antibiotics, prokinetics, or any other drug known to influence colonic flora or gastrointestinal motility in the month preceding the study. All patients with known causes of secondary osteoporosis other than lactose intolerance will be not included in the soubgroup evaluating bone markers.

发起方

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE